{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-009722","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.059457+00:00","generated_at":"2026-05-16T10:54:33.656480+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026","bullets":["Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.","FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.","BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.","Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.","Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-009722","json":"https://secwatch.observer/filing/0001193125-26-009722.json","markdown":"https://secwatch.observer/filing/0001193125-26-009722.md","text":"https://secwatch.observer/filing/0001193125-26-009722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/0001193125-26-009722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000119312526009722/beam-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:54:33.656480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}